FDA approves Quill's tissue repair device:
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale Quill Medical's barbed polydioxanone suture for closing wounds in dermal tissue. The product represents the first in a line of tissue repair devices being developed by the company, that enables sutures to "self-anchor" themselves in tissue without the surgeon having to perform a suture knot, said the Research Triangle Park, North Carolina-based firm. Quill Medical CE marked the product for sale in Europe in May.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.